Ganot Capital

Notal Vision develops home-based monitoring systems for patients with age-related macular degeneration. Founded in 2000, the company operates from offices in Tel Aviv, Israel, and Manassas, Virginia. It offers the ForeseeHome device, which enables patients to detect changes in their vision associated with the condition. This device employs Preferential Hyperacuity Perimetry technology to identify subtle vision alterations. Additionally, Notal Vision provides the Notal OCT Analyzer, an algorithm that automates the detection of pathological fluid in exudative retinal diseases, and utilizes optical coherence tomography for noninvasive imaging. The company's platform incorporates AI algorithms to enhance diagnostic decision-making and facilitate patient-activated treatment options. By extending eye disease management from clinical settings to home environments, Notal Vision aims to improve visual outcomes and enable early intervention by eye care professionals.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). By addressing the underlying causes of MGD, Azura aims to improve the health and quality of life for millions affected by this and other ocular surface diseases, where effective treatment options are often limited. The company is advancing a unique portfolio of compounds in conjunction with a novel drug delivery platform, enabling healthcare professionals to better manage these conditions. Based in Tel Aviv-Yafo, Israel, Azura also has operational presence in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of novel ocular therapies.

Notal Vision is developing the first comprehensive diagnostic solution for the early detection and frequent monitoring of Age-Related Macular Degeneration (AMD), the leading cause of blindness in the western world today. Early detection of ARM can allow doctors to treat patients at an earlier stage and possibly prevent any loss of sight. A true pioneer in the eye care industry, Notal Vision has developed and introduced the first home-based monitoring system for AMD patients, the ForeseeHome™ AMD Monitoring Program.

Notal Vision develops home-based monitoring systems for patients with age-related macular degeneration. Founded in 2000, the company operates from offices in Tel Aviv, Israel, and Manassas, Virginia. It offers the ForeseeHome device, which enables patients to detect changes in their vision associated with the condition. This device employs Preferential Hyperacuity Perimetry technology to identify subtle vision alterations. Additionally, Notal Vision provides the Notal OCT Analyzer, an algorithm that automates the detection of pathological fluid in exudative retinal diseases, and utilizes optical coherence tomography for noninvasive imaging. The company's platform incorporates AI algorithms to enhance diagnostic decision-making and facilitate patient-activated treatment options. By extending eye disease management from clinical settings to home environments, Notal Vision aims to improve visual outcomes and enable early intervention by eye care professionals.

Azura Ophthalmics is a clinical-stage company focused on developing innovative treatments for Meibomian Gland Dysfunction (MGD), a leading cause of dry eye disease (DED). By addressing the underlying causes of MGD, Azura aims to improve the health and quality of life for millions affected by this and other ocular surface diseases, where effective treatment options are often limited. The company is advancing a unique portfolio of compounds in conjunction with a novel drug delivery platform, enabling healthcare professionals to better manage these conditions. Based in Tel Aviv-Yafo, Israel, Azura also has operational presence in Australia and the United States, supported by a management team with a strong track record in the development and commercialization of novel ocular therapies.

Kyma Medical Technologies is a very early stage medical device company in the cardiovascular diagnostic arena. Kyma was founded in March 2008 and is developing a dual modality non-invasive non-ionizing diagnostic system for in stent restenosis detection.